Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study

Table 2 FEV₁ at clinic visits and Clinical COPD Questionnaire (CCQ) scores during the 2-week double-blind treatment period

Variable	Time point	Budesonide/formoterol	Prednisolone + formoterol	N*
FEV ₁ , L	Baseline	1.17 (0.35)	1.20 (0.36)	49/51
	1 week	1.25 (0.45)	1.23 (0.34)	49/51
	2 weeks	1.27 (0.43)	1.29 (0.40)	49/51
FEV ₁ , change from baseline, %	1 week	6.84 (23)	2.50 (24)	49/51
	2 weeks	8.55 (24)	7.50 (29)	49/51
FEV ₁ , % predicted	Baseline	44.8 (9.2)	44.4 (9.4)	49/51
	1 week	47.4 (12.1)	46.0 (11.3)	49/51
	2 weeks	48.3 (12.0)	47.9 (12.4)	49/51
CCQ, score 0–6	Baseline	3.30 (0.95)	3.35 (1.02)	45/51
	1 week	2.67 (1.25)	2.58 (1.11)	45/51
	2 weeks	2.52 (1.19)	2.32 (1.11)	45/51

Data are presented as means and standard deviations. * Refers to patients in the budesonide/formoterol and prednisolone + formoterol groups, respectively with recordings at all visits.

ISSN: 1465-993X